Taiwan · Delayed Price · Currency is TWD GlycoNex Incorporation Company Description
GlycoNex Incorporation engages in the development of cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies in Taiwan.
The company’s development pipeline for the treatment of solid tumors includes GNX102, a humanized monoclonal antibody, currently under phase 1 clinical stage; GNX201, an antibody drug currently under preclinical stage; GNX203, glycan-directed antibody drug currently under the lead optimization stage; and GNX1021, a first-in-class antibody–drug conjugate currently under preclinical stage.
It is also involved in the development of SPD (Denosumab), a humanized IgG2 antibody that is in phase 3 clinical trial for the treatment of osteoporosis and cancer bone metastases.
The company was incorporated in 2001 and is based in New Taipei City, Taiwan.
| Country | Taiwan |
| Founded | 2001 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Mei-Chun Yang |
Contact Details
Address: No. 97, Xintai 5th Road New Taipei City, 221 Taiwan | |
| Phone | 886 2 2697 4168 |
| Website | glyconex.com.tw |
Stock Details
| Ticker Symbol | 4168 |
| Exchange | Taipei Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| ISIN Number | TW0004168000 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Mei-Chun Yang | President, Chief Executive Officer, General Manager and Director |
| Ti-Fen Wu | Chief Financial Officer, Financial and Accounting Manager and Accounting Supervisor |
| Yaohua Lu | Deputy GM and Corporate Governance Officer |